Delving into the Latest Updates on Banner Life Sciences LLC with Synapse

Overview

Basic Info

Introduction

Banner Life Sciences is a pharmaceutical company that specializes in clinical trials. It is based in High Point, NC.

Tags

Nervous System Diseases

Immune System Diseases

Other Diseases

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Chemical drugs	1

Top 5 Target	Count

Nrf2(Nuclear factor erythroid 2-related factor 2)	1

BACKGROUNDTecfidera^® (dimethyl fumarate [DMF]) is an approved product for the treatment of relapsing forms of multiple sclerosis. Monomethyl fumarate (MMF) is the only active metabolite of DMF and is responsible for its therapeutic efficacy.OBJECTIVEThe objective of this study was to determine whether two Bafiertam™ capsules each containing 95 mg of MMF is bioequivalent to one Tecfidera^® capsule containing 240 mg of DMF, a prodrug of MMF.METHODSThis was a single-dose, open-label, randomized, two-way crossover study evaluating two treatments over two periods with a washout interval between treatments. Fifty healthy subjects were randomized to receive a single dose of the test drug MMF 190 mg as 2 × 95 mg delayed-release capsules or the reference drug DMF 240 mg as a 1 × 240-mg delayed-release capsule. Blood samples were obtained prior to dosing and at prespecified time points through 24 h post-dose to determine plasma concentrations of MMF. The pharmacokinetic parameters of MMF were calculated including maximum observed concentration, time to reach maximum observed concentration, apparent half-life of the drug in plasma, AUC_0-t which is the area under the plasma concentration-time curve (AUC) from time zero (dosing time) to the last time point, t, with measurable analyte concentration, and AUC_0-inf, which is AUC_0-t plus the extrapolated AUC from time t to infinity.RESULTSThe geometric least-squares mean ratios (90% confidence interval) of the test drug MMF vs the reference drug DMF were 96.80% (92.18-101.64), 96.35% (91.81-101.12), and 104.84% (95.54-115.05) for AUC_0-t, AUC_0-inf, and maximum observed concentration, respectively. Two capsules of Bafiertam™ was safe and generally well tolerated. The most common adverse event for both products was flushing, 60% and 51%, for Bafiertam™ and Tecfidera^®, respectively.CONCLUSIONSBased on the statistical analysis results of the pharmacokinetic parameters of MMF, a single oral dose of two Bafiertam™ DR 95 mg capsules is bioequivalent to a single oral dose of one Tecfidera^® DR 240 mg capsule.CLINICAL TRIAL REGISTRATIONThis study was retrospectively registered with ClinicalTrials.gov (NCT04570670) on 30 September, 2020.

100 Deals associated with Banner Life Sciences LLC

Login to view more data

100 Translational Medicine associated with Banner Life Sciences LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data